Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Lihpao Life Science Corp. is navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is limited to 1 distinct examiner and 1 distinct art unit. Such a concentrated distribution reflects a singular focus in the company's current patenting efforts within the biotechnology sector. For the company, this means that the success of their current intellectual property strategy relies on the specific examination standards of the 1 art unit involved.
WRIGHT, ERIC BRANDON serves as the busiest examiner for this portfolio, managing 1 pending office action. This 1 action constitutes the entire pending workload for the company. The fact that 1 distinct examiner is responsible for the 1 pending office action indicates that there is no overlap or division of labor across different examiners for these specific filings. Practitioners should focus on the specific preferences and past rulings of this examiner, as they currently hold sole authority over the company's pending biotechnology claims.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WRIGHT, ERIC BRANDON | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18876664 | METHOD FOR PRODUCING MATURE DENDRITIC CELLS | WRIGHT, ERIC BRANDON | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18876664 | METHOD FOR PRODUCING MATURE DENDRITIC CELLS | WRIGHT, ERIC BRANDON | 1632 | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLihpao Life Science Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Eric Brandon Wright has the most, with 1 of Lihpao Life Science Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
